Cardiovascular complications of diabetic kidney disease - PubMed (original) (raw)
Review
Cardiovascular complications of diabetic kidney disease
Ragnar Pálsson et al. Adv Chronic Kidney Dis. 2014 May.
Abstract
Diabetic nephropathy is the most common cause of CKD and represents a large and ominous public health problem. Patients with diabetic kidney disease have exceptionally high rates of cardiovascular morbidity and mortality. In fact, the excess mortality among patients with diabetes appears to be largely limited to the subgroup with kidney disease and explained by their high burden of cardiovascular disease. The mechanisms underlying the strong association between diabetic kidney disease and various forms of cardiovascular disease are poorly understood. Traditional risk factors for cardiovascular disease, although prevalent among those with diabetes, do not fully account for the heightened risk observed. Despite their susceptibility to cardiovascular disease, patients with CKD are less likely to receive appropriate risk factor modification than the general population. Moreover, because patients with CKD have commonly been excluded from major cardiovascular trials, the evidence for potential treatments remains limited. The mainstays of treatment for diabetic kidney disease currently include blockade of the renin-angiotensin-aldosterone system and control of hypertension, hyperglycemia, and dyslipidemia. Increased awareness of the vulnerability of this patient population and more timely interventions are likely to improve outcomes while large evidence gaps are filled with newer studies.
Keywords: CKD; Coronary artery disease; Diabetes mellitus; ESRD.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1
Overview of major established and proposed mechanisms of CVD in patients with DM and CKD.
Similar articles
- Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H, Lazich I, Bakris GL. Yamout H, et al. Adv Chronic Kidney Dis. 2014 May;21(3):281-6. doi: 10.1053/j.ackd.2014.03.005. Adv Chronic Kidney Dis. 2014. PMID: 24780456 Review. - [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
Zaoui P, Hannedouche T, Combe C. Zaoui P, et al. Nephrol Ther. 2017 Jun;13(6S):6S16-6S24. doi: 10.1016/S1769-7255(18)30036-1. Nephrol Ther. 2017. PMID: 29463395 Review. French. - Hemodialysis.
Murdeshwar HN, Anjum F. Murdeshwar HN, et al. 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33085443 Free Books & Documents. - Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, Fogarty D, Frankel AH, Karalliedde J, Mark PB, Patel DC, Pokrajac A, Sharif A, Zac-Varghese S, Bain S, Dasgupta I; Association of British Clinical Diabetologists and The Renal Association. Banerjee D, et al. BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5. BMC Nephrol. 2022. PMID: 34979961 Free PMC article. - Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the kidney is good for the heart and brain.
Toto RD. Toto RD. Am J Hypertens. 2004 Nov;17(11 Pt 2):7S-10S; quiz A2-4. doi: 10.1016/j.amjhyper.2004.08.003. Am J Hypertens. 2004. PMID: 15539108 Review.
Cited by
- Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial.
Donate-Correa J, Ferri CM, Mora-Fernández C, Pérez-Delgado N, González-Luis A, Navarro-González JF. Donate-Correa J, et al. Cardiovasc Diabetol. 2024 Aug 24;23(1):314. doi: 10.1186/s12933-024-02393-x. Cardiovasc Diabetol. 2024. PMID: 39182114 Free PMC article. Clinical Trial. - Impact of chronic kidney disease and end-stage renal disease on the mid-term adverse outcomes in diabetic patients with cardiovascular diseases.
Chou CL, Chiu HW, Hsu YH, Yu SM, Liou TH, Sung LC. Chou CL, et al. Sci Rep. 2024 Jul 9;14(1):15770. doi: 10.1038/s41598-024-66655-0. Sci Rep. 2024. PMID: 38982230 Free PMC article. - Triglyceride Glucose Index for the Detection of Diabetic Kidney Disease and Diabetic Peripheral Neuropathy in Hospitalized Patients with Type 2 Diabetes.
Tu Z, Du J, Ge X, Peng W, Shen L, Xia L, Jiang X, Hu F, Huang S. Tu Z, et al. Diabetes Ther. 2024 Aug;15(8):1799-1810. doi: 10.1007/s13300-024-01609-3. Epub 2024 Jun 22. Diabetes Ther. 2024. PMID: 38907937 Free PMC article. - Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.
Piko N, Bevc S, Hojs R, Ekart R. Piko N, et al. Pharmaceuticals (Basel). 2024 Mar 26;17(4):418. doi: 10.3390/ph17040418. Pharmaceuticals (Basel). 2024. PMID: 38675379 Free PMC article. Review. - Modification of coronary artery disease clinical risk factors by coronary artery disease polygenic risk score.
Truong B, Ruan Y, Haidermota S, Patel A, Surakka I, Hornsby W, Koyama S, Lee SH, Natarajan P. Truong B, et al. Med. 2024 May 10;5(5):459-468.e3. doi: 10.1016/j.medj.2024.02.015. Epub 2024 Apr 19. Med. 2024. PMID: 38642556
References
- CDC statistics Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
- Shaw JE, Sicree R a, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010;87(1):4–14. - PubMed
- Kannel WB. Diabetes and Cardiovascular Disease. The Framingham Study. JAMA. 1979;241(19):2035. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 DK096493/DK/NIDDK NIH HHS/United States
- R01 DK093938/DK/NIDDK NIH HHS/United States
- R01DK093938/DK/NIDDK NIH HHS/United States
- P30DK096493/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical